TSLA +5.2% on analyst upgrade citing SpaceX; WELL beats Q3 FFO

Monday closed with five S&P constituents moving 3% or more and Welltower's quarterly results leading the earnings calendar.

Welltower: FFO beat, guidance raised

$WELL reported Q3 normalized funds from operations of $1.67 per share against the $1.64 consensus estimate — a $0.03 beat. Operating income grew 15.8% year-over-year; normalized FFO expanded 24.6%. The company raised its full-year profit guidance, citing occupancy and revenue-per-occupied-room gains across senior housing. One wire headline early in the session flagged a miss; it referenced a non-FFO metric. The 8-K tells a different story.

SpaceX's $40 billion compute lease and Tesla's upgrade

$SPCX disclosed a material corporate event: SpaceX has agreed to lease $40 billion in computing equipment for AI data centers, a commitment that ranks among the largest single infrastructure deals in the AI buildout to date. On the same day, $TSLA rose 5.2%. An analyst upgrade cited core business strength and a potential SpaceX merger as the primary rationale, moving the stock to a buy zone on a raised price target. Fort Bend County separately announced sweetened incentives to attract a $10 billion Tesla solar panel manufacturing facility. Tesla's $5 billion reduction in planned AI capex was reframed by the same analysts as deliberate capital allocation — the company is not building hyperscale data centers, freeing cash toward robotaxi and robotics programs.

Power and defense

$GEV rose 4.9% on a contracted order: a gas turbine and generator set for a 372-megawatt combined-cycle power plant in Côte d'Ivoire, signed ahead of GEV's own earnings report due this week. $RTX gained 3.4%; Q3 results included disclosure of a $340 billion record order backlog — the forward revenue visibility that anchors defense-sector valuations against a backdrop of rising military budgets.

Intel and Merck move in opposite directions

$INTC added 4.0% as chip-sector names found broad support ahead of Intel's own Q3 earnings report, due this week. Revenue growth is running at 25% year-over-year — stabilizing, though well below Nvidia's 106% pace. The result itself is pending. $MRK fell 3.2%. New U.S. restrictions on Chinese biotech partnerships complicate Merck's drug-candidate sourcing pipeline, a cost-and-timeline risk that compounds existing pressure around Keytruda's approaching exclusivity expiry. A Phase 3 trial in endometrial cancer showed a 32% reduction in mortality versus chemotherapy, with an FDA decision scheduled for June 2027 — a meaningful datapoint, but not one that moved Monday's close.

Filings desk

P&G CEO Shailesh Jejurikar sold $2.96 million in $PG shares Monday, per a large insider transaction filing.

What we set aside

Two filings were held — disclosed today but tied to events more than 36 hours old. Five tickers examined in the sweep (DLR, FCX, GE, UNH, VST) produced no substantive filings or news inside the freshness window.

The desk is watching Intel's Q3 earnings, GE Vernova's results, and the broader megacap reporting wave — Microsoft, Amazon, and Alphabet are all scheduled this week.